# 1. Financial Performance ## A. Key Figures * **Q2 FY2026 Operating Income:** **₹7,339 Mn** (+14% YoY) * H1 FY2026 Operating Income: ₹13,171 Mn (+9% YoY) · EBITDA: ₹1,310 Mn (–1% YoY) · EBITDA Margin: 9.95% · Net Profit: ₹984 Mn (+3%) · PAT Margin: 7.47% * Q2 EBITDA: ₹685 Mn (flat YoY) · EBITDA Margin: 9.33% · Net Profit: ₹499 Mn (–1.4% YoY) · PAT Margin: 6.8% ## B. Revenue Growth * **Rebound in Q2:** Revenue growth recovered to strong double-digit levels after a weak first quarter impacted by SAP migration and engineering margin pressures. * **Normalization Underway:** Operational stabilization post-SAP implementation is driving improved execution and top-line momentum. ## C. Profit Margins * **Margin Resilience:** Despite near-flat EBITDA and slight net profit decline in Q2, margins remained robust, supported by **higher-margin project wins** in recent quarters. * **Cost Reclassification:** Material costs now include direct EPC contract expenses per accounting standards, aligning with industry practice and affecting P&L structure. ## D. Balance Sheet * **Debt Build-Up for Growth:** Gross debt rose to **₹400+ Cr** in Q2, with a further **₹50 Cr increase expected**, primarily funding strategic expansion and acquisitions. * **Roha Capitalization Impact:** **₹350 Cr** transferred from CWIP to gross block in H1; remaining **₹200 Cr CWIP** to be fully capitalized by year-end, triggering an **annualized depreciation of ₹40 Cr** from Q3. * **Strategic Acquisition Paydown:** Debt from MAPRIL acquisition is being repaid, positioning the asset as a growth platform for European expansion. --- # 2. Order Book & Inflows ## A. Key Figures * **Order Book:** **₹2,711 Cr** (current) · **₹470 Cr** quarterly inflow * **Bid Pipeline:** **₹9,011 Cr** offer bank · **15–20%** win ratio ## B. Current Order Book * **Profitability Upside:** Order book includes several higher-margin projects set to commence in Q3 and Q4, supporting improved overall profitability. * **Strategic Capacity Build:** Continued investment in standard system engineering facilities to expand innovative off-the-shelf product offerings. ## C. Quarterly Inflows * **Inflow Momentum:** Strong quarterly order inflow reflects robust demand across domestic and international markets. * **Selective Project Acquisition:** Higher inflow compared to Q1 driven by disciplined bidding, informed by legacy project experience. ## D. Bid Pipeline * **Pipeline Resilience:** Engineering offer bank has consistently remained in the **₹8,000–9,000 Cr** range over multiple years, with ongoing expansion efforts. * **Execution Timing:** While some bids expected to close by March 2026, others will spill into the next fiscal year due to variable decision timelines. * **Sector Diversification:** Current pipeline predominantly driven by private sector and PSUs, with limited exposure to government and infrastructure segments. --- # 3. Segment Performance ## A. Key Figures * Engineering Revenue: **₹456.2 Cr** (Qtr, +16% YoY) * Engineering EBIT: **₹224 Mn** (Qtr, -5% YoY) * **Chemical Revenue:** **₹21.84 Cr** (Qtr, +11% YoY) · **EBIT:** **₹5.91 Cr** (+13% YoY) * Consumer Products Revenue: ₹858Mn (+24% YoY) · Loss: ₹27Mn (vs. ₹35Mn loss YoY) ## B. Engineering Division * **Growth with Margin Pressure:** Revenue rose on strong order inflows in ultra-pure and high-purity water projects for solar and pharma, though EBIT declined due to elevated infrastructure costs and **slow execution in Uttar Pradesh** amid funding constraints. * **Backlog Execution Improving:** Q2 recovery driven by release of latent order backlog post-SAP implementation, with billing momentum returning across ongoing EPC contracts. * **International Confidence Building:** Sri Lanka project over **90% complete** with healthy cash flows, boosting credibility in overseas markets. * **Strategic Reorientation:** Focus on technology-intensive EPC areas (desalination, wastewater, ultra-pure water) to improve margin profile; services and digital offerings being scaled for recurring revenue. ## C. Chemical Business * **Stable Margin Expansion:** Delivered double-digit EBIT growth on **11% revenue increase**, supported by supply-constrained market dynamics and strong demand in resin and chemical lines. * **Post-SAP Recovery Underway:** H1 growth muted at 2% due to system disruption, but Q2 rebounded with **9%+ YoY growth**, signaling normalization and confidence in sustaining this pace. * **Full-Year Guidance Set:** Management expects **9–10% YoY revenue growth** for the segment despite no location-specific guidance. ## D. Consumer Products * **Strong Volume-Led Growth:** Revenue surged on **24% YoY increase**, fueled by leadership in softeners, market share gains, and successful launches of **alkaline and hydrogen water products**. * **Loss Widening Amid Investment Phase:** Despite higher losses, the expansion reflects continued investment in brand building and geographic reach. * **Brand & Geographic Expansion:** 'Bharat Ka Pani' campaign and FM radio presence enhancing recall; early success reported in **Nepal market entry**. --- # 4. Capacity & Commissioning ## A. Key Figures * **CAPEX (H1):** **₹160 Cr** (₹120 Cr for Roha plant) * **Roha Plant Capacity Addition:** **~10%** to overall manufacturing capacity * **Initial Capacity Utilization:** **~25%** in first 12 months of production * **Commissioned Manufacturing Capacity:** **10%** as of current date ## B. Roha Plant Ramp-up * **Ahead-of-Schedule Commissioning:** Greenfield Roha plant began stage-wise commercialization in **late September 2025**, ahead of initial H1 target, signaling strong execution capability. * **Strategic Capacity Expansion:** New facility addresses **full-capacity constraints** at existing plant; all output is being sold, validating demand absorption. * **Phased, Quality-Driven Scale-Up:** Ramp-up is deliberate due to **stringent quality controls**, **process optimization needs**, and **global export compliance**, supporting premium product positioning. * **High Capitalization Efficiency:** Utilities and service centers are fully capitalized despite limited production, enabling faster future manufacturing scale-out. ## C. Full Utilization Timeline * **Near-Term Utilization Target:** Already-commissioned **10% capacity** to be **fully utilized before FY-end**, with ramp-up progressing toward proposed levels. * **Long-Term Ramp-Up Outlook:** Optimal capacity utilization expected over **three to four years**, aligned with global demand growth and market absorption capacity. ## D. Technology Upgradation * **First-of-Its-Kind Investment:** ₹180 Cr dedicated to **cutting-edge resin technology**, positioning the company as a domestic innovator and enhancing long-term competitiveness. --- # 5. Product & Technology ## A. Membrane Portfolio * **Local Production & Cost Edge:** Leveraging MANN+HUMMEL’s proven global membrane technology, the company will produce advanced membranes locally at its state-of-the-art facility, reducing import dependence and boosting cost efficiency and competitiveness. * **Established Market Position:** Confidence in the portfolio underscored by multiple market-leading products driving consistent performance. * **Comprehensive Product Range:** Offers RO (brackish, seawater, fouling-resistant), ultrafiltration (PES, PVDF), and nano-filtration membranes, with expanded capabilities from the collaboration. * **High-Growth Strategic Focus:** Membrane technology is a key investment area due to its significant market potential and alignment with global water treatment trends. ## B. Strategic Partnerships * **Co-Branded Manufacturing Alliance:** Strategic partnership with MANN+HUMMEL Water & Membrane Solutions for manufacturing hollow-fibre UF and MBR membranes in India under the HYDRAMEM and MANN+HUMMEL co-brand. * **Sole Domestic Partner, Global Commercialization Rights:** Alliance positions the company as MANN+HUMMEL’s exclusive Indian manufacturing partner and enables global commercialization of the technology in its operational markets. * **Technology Licensing, Not JV:** Structure is a licensing agreement—no joint venture—allowing production at the existing Goa plant with potential **royalty payments** to MANN+HUMMEL. * **Mutual Strategic Benefits:** Ion Exchange gains technological depth and global manufacturing hub status; MANN+HUMMEL accesses low-cost production and expanded footprint. * **MAPRIL Acquisition Integration:** Acquired foreign entity MAPRIL is performing well, with trained teams actively promoting the Ion Exchange portfolio using local presence. ## C. Innovation Focus * **Access to Advanced Applications:** Partnership unlocks cutting-edge capabilities in membrane bioreactor (MBR) for wastewater, hot sanitizable RO for biopharma, and enhanced ultrafiltration. * **Strategic Growth in High-Demand Segments:** Membrane technology is a core growth driver, aligned with rising global demand for wastewater treatment and desalination. --- # 6. Margins & Project Risks ## A. Key Figures * **Chemical Business Margin:** **~29%** (all-time high) ## B. Legacy Project Impact * **Severe Margin Pressure:** Engineering margins hit multi-year lows due to **legacy project overruns**, slow execution in UP, and fixed cost drag despite lower revenue recognition. * **Resumed Progress on Sri Lanka Project:** Customer funding reinstated with satisfaction expressed, supporting near-term execution momentum. * **Legacy Drag to Persist:** Onerous contracts will continue impacting margins through FY'26, with **no immediate return to prior double-digit levels** due to aggressive pricing in large projects. * **Strategic Shift in Order Intake:** Company now applying stricter margin discipline, becoming more selective to avoid repeat of unprofitable project commitments. ## C. Engineering Margin Outlook * **Gradual Recovery Expected:** Margins forecast to improve to **6–7% in H2 FY'25**, supported by billing ramp-up of higher-margin projects in Q3 and Q4. * **Future Margin Rebuilding:** Leadership targets **high single-digit EBIT margins** in engineering through focus on **short-cycle, value-added, and technology-driven offerings**, with intent to return to **double-digit margins** over time. * **Chemical Segment Strength:** Margins reached record levels near **29%**, though sustainability depends on managing commodity and FX volatility. ## D. Pricing Competition * **Quality Over Speed:** Pricing strategy during ramp-up emphasizes meeting international standards and inventory clearance, not aggressive market share capture. --- # 7. Guidance & Outlook ## A. Key Figures * **CAPEX (Roha Plant):** **₹450 Cr** (total estimated) * **CAPEX (Ex-Roha):** **₹80–100 Cr** (full-year guidance) ## B. Revenue Projections * **Strategic Growth Trajectory:** High-potential segment expected to scale toward ₹500 Cr over time, with full capacity utilization targeted within **three to four years**. * **No Formal Guidance:** Management declines to provide specific revenue or timing guidance, emphasizing long-term portfolio growth over near-term targets. ## C. Margin Recovery * **Path to Profitability:** Segment not yet at break-even; margins expected to improve sequentially in H2 FY'25 amid reinvestment of all earnings. * **Growth-First Strategy:** Reinvestment focused on market share capture, distribution expansion, and retail presence, delaying near-term profitability. ## D. CAPEX Plans * **Technology-Led Investment:** Roha plant CAPEX fully outlined; incremental spend possible for membrane scaling, supported by access to **world-class technology** via collaboration. * **Indigenous Development Continues:** Investment complements ongoing in-house R&D, accelerating time-to-market without reliance on external funding.